C12N 2740/16043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2740/16043 (Viral genome or elements thereof as genetic vector) appears on 984 US grants and 2,520 published applications in this corpus.
Search patents in C12N- Granted patents
- 984
- Published applications
- 2,520
- Assignees
- 1,002
- Inventors
- 5,123
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 6 | 0 |
| 1998 | 10 | 0 |
| 1999 | 12 | 0 |
| 2000 | 12 | 0 |
| 2001 | 16 | 4 |
| 2002 | 12 | 13 |
| 2003 | 14 | 40 |
| 2004 | 10 | 28 |
| 2005 | 10 | 33 |
| 2006 | 6 | 22 |
| 2007 | 18 | 17 |
| 2008 | 7 | 33 |
| 2009 | 14 | 19 |
| 2010 | 13 | 29 |
| 2011 | 7 | 31 |
| 2012 | 17 | 25 |
| 2013 | 16 | 22 |
| 2014 | 18 | 34 |
| 2015 | 16 | 36 |
| 2016 | 21 | 49 |
| 2017 | 29 | 62 |
| 2018 | 39 | 94 |
| 2019 | 40 | 152 |
| 2020 | 63 | 164 |
| 2021 | 56 | 223 |
| 2022 | 75 | 305 |
| 2023 | 99 | 267 |
| 2024 | 108 | 334 |
| 2025 | 129 | 309 |
| 2026 | 86 | 175 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Immune cells with enhanced cytotoxicity and methods of use thereof29 Sep 2026US 12,747,443 B2Ludwig Institute for Cancer Research
- Self-inactivating lentiviral vector comprising a FoxP3 expression cassette29 Sep 2026US 12,747,454 B2The Board of Trustees of the Leland Stanford Junior University
- Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof15 Sep 2026US 12,735,471 B2iCell Gene Therapeutics Inc.
- Non-viral transgenesis15 Sep 2026US 12,735,719 B2The Regents of the University of California
- Methods of treating mitochondrial disorders1 Sep 2026US 12,723,062 B2The Regents of the University of California
- Cell surface engineered of tailored therapeutic gene delivery8 Oct 2026US 2026/0308617 A1The Children’s Hospital of Philadelphia
- Retroviral vectors8 Oct 2026US 2026/0308619 A1UCL Business PLC
- Rapamycin resistant cells8 Oct 2026US 2026/0308637 A1Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Recombinant enzyme for the accurate insertion of dna sequences in eukaryotic cells1 Oct 2026US 2026/0297624 A1Rensselaer Polytechnic Institute
- Chimeric antigen receptors and their derivatives and applications17 Sep 2026US 2026/0272980 A1Fudan University
Most cited
By later US patents
- Vector and method of use for nucleic acid delivery to non-dividing cells323US 6,013,516 AThe Salk Institute for Biological Studies · 2000
- Method and means for producing high titer, safe, recombinant lentivirus vectors261US 5,994,136 ACell Genesys, Inc. · 1999
- Biocompatible implant for the expression and in vivo secretion of a therapeutic substance151US 5,906,817 AInstitut Pasteur · 1999
- Use of triplex structure DNA in transferring nucleotide sequences98US 6,682,907 B1Institut Pasteur · 2004
- Therapeutic ribozyme compositions and expression vectors92US 5,225,347 AInnovir Laboratories, Inc. · 1993